Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
ApprovedVaccine
Nonavalent HPV vaccine (9vHPV/Gardasil-9™). is one of 43 biologic programs targeting Papilloma. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
150 competitors in Papilloma
#DrugCompanyPhaseTrials
1Cervarix
GSKPhase 3
GSK 257049
GSKPhase 3
Comparator: Pbo
Merck & Co.Phase 3
Gardasil
Merck & Co.Phase 3
Havrix
GSKPhase 3
Engerix-B
GSKPhase 3
Fludara
SanofiPhase 2
Taxol
TevaPhase 2
Tecentriq
RochePhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Papilloma1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Approved[1]
- Company
- MMiquel Angel Pavon Ribas